#USA #Dublin #Jazz Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Releases Q2 2026 Financial Results

On August 3rd, 2026, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced its financial outcomes for the second quarter of 2026 (Q2 2026), showcasing robust performance and promising future projections. The company reported record total revenues of $1.2 billion, marking a substantial 16% growth year-over-year, significantly impacting their revenue forecasts for the year.

Financial Highlights

The second quarter results highlighted remarkable commercial execution, reflecting a strong momentum across various segments of the business. CEO Renee Gala stated, “Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance.”

Alongside the revenue boost, Jazz Pharmaceuticals generated impressive adjusted earnings per share (EPS), reported at $2.78 GAAP EPS and $5.71 non-GAAP EPS, with nearly $824 million in cash from operations during the first half of 2026.

Key Revenue Drivers

The growth in total revenues can be attributed largely to the success of several key products:

• - Xywav (an oral solution for narcolepsy) saw its sales increase 13% year-over-year, reaching $471 million, alongside approximately 525 new patients added in Q2 2026.
• - Epidiolex, utilized for treating certain types of epilepsy, also experienced a 16% revenue growth, with sales climbing to $292 million in the same period.
• - Additionally, the company is preparing for the imminent launch of Ziihera (zanidatamab) for HER2-positive gastroesophageal adenocarcinoma (GEA), with the FDA setting a PDUFA date of August 25, 2026.

Expanded Pipeline and Future Prospects

Jazz Pharmaceuticals' expansion plans are around not just existing products but also promising candidates in their pipeline. The company has made considerable strides in advancing both the zanidatamab and Epidiolex clinical programs while prioritizing research and development efforts to bolster long-term growth.

In a recent key development, the FDA granted a Breakthrough Therapy designation for zanidatamab in treating previously treated locally advanced or metastatic HER2-positive colorectal cancer (CRC). This designation intends to expedite the development and review process for therapies that treat serious conditions, marking a significant milestone for the company.

Adjusted Revenue Forecast

Reflecting the strong commercial execution seen in the first half of the year, Jazz Pharmaceuticals has raised its revenue guidance for 2026, now projected to be between $4.60 billion and $4.75 billion. This new estimate anticipates continued double-digit year-over-year revenue growth for both Xywav and the combined epilepsy and oncology franchises moving forward.

In conclusion, with its strong foundation and strategic pipeline expansion, Jazz Pharmaceuticals is poised to deliver meaningful innovations for patients while providing substantial value to its shareholders. As the company gears up for pivotal product launches and further development, the coming months are pivotal for its growth trajectory in the biopharmaceutical landscape.